Purpose Evidence comparing minimally invasive approaches for pediatric pilonidal sinus disease (PSD) is limited. We aimed to compare the effectiveness of Sinus Laser-Assisted Closure (SiLaC) and Pediatric Endoscopic Pilonidal Sinus Treatment (PEPSiT), with particular emphasis on wound healing and disease recurrence. Methods A retrospective single-center cohort study was conducted including patients younger then 18 years of age treated for PSD between January 2022 and December 2025. The primary outcome was wound healing time. Secondary outcomes included recurrence rate and operative time. Results Seventy-three patients were included: 21 underwent SiLaC and 52 underwent PEPSiT. Baseline demographic characteristics were comparable between groups. Median wound healing time was significantly shorter following SiLaC than PEPSiT (15 [IQR 15–22] vs. 55.5 [IQR 24.3–113.3] days; p < 0.001). Recurrence rates did not differ significantly (14.3% vs. 23.1%; p = 0.492), nor did median operative time (18 vs. 22 minutes; p = 0.089). Follow-up was shorter in the SiLaC group (2 vs. 5 months; p = 0.026). Conclusions SiLaC was associated with significantly faster wound healing and similar short-term recurrence rates. Its compatibility with lateral positioning and with local or locoregional anaesthesia may further enhance postoperative recovery. Prospective studies with longer follow-up are warranted to confirm long-term efficacy and cost-effectiveness.
Résumé Le virus de l’encephalite a tiques (TBEV pour tick-borne encephalitis virus) est responsable de l’encephalite a tiques (TBE pour tick-borne encephalitis), zoonose transmise a l’humain par piqure de tique du genre Ixodes, et plus rarement par ingestion de produits laitiers contamines. Au cours de la derniere decennie, l’epidemiologie de la TBE a beaucoup evolue en Europe avec une incidence en augmentation dans les pays endemiques et de nouvelles zones de circulation du virus. En France, une trentaine de cas sont rapportes chaque annee, dont la majorite sont recenses en Alsace, foyer “historique”, et en region Auvergne-Rhone-Alpes. En 2020, un premier foyer d’infection alimentaire (44 cas), lie a la consommation de fromage de chevre au lait cru a ete identifie dans le departement de l’Ain. La survenue de ce foyer associee a l’augmentation des cas rapportes a conduit a l’inscription de la TBE au registre des maladies à declaration obligatoire en mai 2021. La definition des cas confirmes repose sur un ensemble de criteres cliniques, diagnostiques et epidemiologiques.Si la plupart des infections causees par le sous-type europeen du virus, circulant en France, sont asymptomatiques, certains patients developpent des tableaux de meningite ou meningoencephalite, associes a des sequelles postinfectieuses (cognitives et/ou motrices) jusqu’a 40 % des cas. S’il n’existe pas de traitement antiviral specifique, un vaccin est disponible. L’emergence de la TBE en Europe, notamment, en France constitue un reel enjeu de sante publique.
To evaluate the impact of deploying AI as the first reader (R1) in a double-reading breast-screening workflow and to characterize second-reader (R2) behavior—including the effect of disclosing whether R1 was AI or human. This retrospective study used a cancer-enriched cohort of 220 women (95 cancers), with prevalence-weighted analyses performed to approximate population screening metrics. Five radiologists and one commercially available AI (Breast-SlimView®, Hera-MI) each served as R1; four radiologists served as R2. For each R2, cases were randomized 1:1 to AI-first versus human-first and, independently, to disclosure versus concealment of R1 identity. R2 could validate, dismiss, or add annotations. The primary endpoint was final decision correctness by breast. We used GEE logistic regression to estimate the overall effect of using AI as the first reader and to isolate second-reader behavior independently of first-reader accuracy. At the prespecified R1 operating point, AI had sensitivity/specificity/accuracy of 85.2
Effectiveness of Occipital Nerve Stimulation (ONS) in refractory chronic cluster headache (rCCH) is supported by series of cases and a unique controlled trial, and its risk/benefit ratio has been questioned. Our objective was to identify predictive factors of ONS effectiveness in rCCH patients, to optimize this risk/benefit ratio and better select eligible patients. We analyzed 125 patients (43 women, mean age 46,4) included prospectively in the “French ONS registry”, suffering from rCCH, treated by ONS for more than one year, and with data concerning putative preoperative predictive factors of effectiveness, including demographic, CCH characteristics and severity, treatment use and co-morbidities. We studied factors associated with ONS response, defined as a ≥ 50
